Poly Medicure Limited (POLYMED) Fair Value & Analysis
Healthcare · IN · Market cap ₹176B
Fair value as of: Jul 3, 2026
From 16 valuation models · updated today
Share price +25.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,191 – ₹2,238 · fair‑value band ₹405.22 – ₹718.49 · the ₹1,678 price screens above the ₹540.29 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Poly Medicure Limited (POLYMED) currently trades at ₹1,678, while our model-based Fair Value estimate is ₹540.29 — implying the stock looks roughly 67.8% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Poly Medicure Limited generated revenue of ₹18.8B at a net margin of 17.2%. Revenue grew 21.3% year over year. It earns a return on equity of 10.9%. Net debt stands at ₹2.7B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Poly Medicure Limited reported revenue of ₹18.8B in FY2026 versus ₹9.2B in FY2022, a compound +19.4%/yr. Reported net income was ₹3.2B in FY2026, compounding +21.8%/yr from FY2022.
Is POLYMED fairly valued? → Check now
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $33.61 | $31.78 | -5% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $66.11 | $36.99 | -44% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Poly Medicure Limited (POLYMED) undervalued?
What is the fair value of POLYMED?
What is the quality score of POLYMED?
What is the revenue of Poly Medicure Limited (POLYMED)?
What is the net profit margin of POLYMED?
Does Poly Medicure Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.